

Serial No.: not yet assigned

acid residues 1 to 180 of SEQ ID NO:1.

45. (New) The isolated polypeptide of Claim 43 which comprises a polypeptide consisting of amino

acid residues 21 to 180 of SEQ ID NO:1.

46. (New) The isolated polypeptide of Claim 43 which comprises a polypeptide consisting of amino

acid residues 1 to 197 of SEQ ID NO:3.

47. (New) The isolated polypeptide of Claim 43 which comprises a polypeptide consisting of amino

acid residues 19 to 197 of SEQ ID NO:3.

48. (New) An isolated polypeptide having at least 80% amino acid sequence identity to a polypeptide

selected from the group consisting of:

(a) a polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209866,

(b) a polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 209866 lacking its associated signal peptide encoding region,

(c) a polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203552, and

(d) a polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203552 lacking its associated signal peptide encoding region.

49. (New) The isolated polypeptide of Claim 48 which comprises a polypeptide encoded by the full-

length coding sequence of the cDNA deposited under ATCC accession number 209866.

50. (New) The isolated polypeptide of Claim 48 which comprises a polypeptide encoded by the

Serial No.: not yet assigned

full-

length coding sequence of the cDNA deposited under ATCC accession number 209866 lacking its associated signal peptide encoding region.

51. (New) The isolated polypeptide of Claim 48 which comprises a polypeptide encoded by the full-

length coding sequence of the cDNA deposited under ATCC accession number 203522.

52. (New) The isolated polypeptide of Claim 48 which comprises a polypeptide encoded by the full-

length coding sequence of the cDNA deposited under ATCC accession number 203522 lacking its associated signal peptide encoding region.

53. (New) A composition of matter comprising a polypeptide selected from the group consisting of:

- (a) a PRO1031 polypeptide comprising amino acid residues 1 to 180 of SEQ ID NO:1,
- (b) a PRO1031 polypeptide comprising amino acid residues 21 to 180 of SEQ ID NO:1,
- (c) a PRO1122 polypeptide comprising amino acid residues 1 to 197 of SEQ ID NO:3, and
- (d) a PRO1122 polypeptide comprising amino acid residues 19 to 197 of SEQ ID NO:3; in combination with a pharmaceutically acceptable carrier.

54. (New) The composition of matter of Claim 53 which comprises a polypeptide comprising amino

acid residues 1 to 180 of SEQ ID NO:1 in combination with a pharmaceutically acceptable carrier.

55. (New) The composition of matter of Claim 53 which comprises a polypeptide comprising amino

acid residues 21 to 180 of SEQ ID NO:1 in combination with a pharmaceutically acceptable carrier.

56. (New) The composition of matter of Claim 53 which comprises a polypeptide comprising amino

Serial No.: not yet assigned

acid residues 1 to 197 of SEQ ID NO:3 in combination with a pharmaceutically acceptable carrier.

57. (New) The composition of matter of Claim 53 which comprises a polypeptide comprising amino

acid residues 19 to 197 of SEQ ID NO:3 in combination with a pharmaceutically acceptable carrier.

A1
Cancelled

58. (New) An article of manufacture comprising:

a container; and

a composition of matter comprising a polypeptide, wherein said polypeptide comprises at least about 80% amino acid sequence identity to:

- (a) a PRO1031 polypeptide comprising amino acid residues 1 to 180 of SEQ ID NO:1,
- (b) a PRO1031 polypeptide comprising amino acid residues 21 to 180 of SEQ ID NO:1,
- (c) a PRO1122 polypeptide comprising amino acid residues 1 to 197 of SEQ ID NO:3, and
- (d) a PRO1122 polypeptide comprising amino acid residues 19 to 197 of SEQ ID NO:3; in combination with a pharmaceutically acceptable carrier.

59. (New) The article of manufacture of Claim 58, further comprising a label affixed to said container, or a package insert included in said container, referring to the use of said composition for the treatment of a degenerative cartilaginous disorder in a mammal.--

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."